InvestmentPitch Media Video Discusses MindBio Therapeutics' Commencement of MB22001 Phase 2 Clinical Trial in World's First Take-Home Microdosing Study for Patients with Depression
This groundbreaking trial represents a global precedent and stands as the sole clinical trial authorized for the take-home usage of LSD.
- This groundbreaking trial represents a global precedent and stands as the sole clinical trial authorized for the take-home usage of LSD.
- Administered at sub-hallucinogenic levels, this therapeutic microdose is taken every third day over an 8-week span in an open-label Phase 2a clinical trial involving 20 participants.
- The primary objective of this Phase 2a trial is to assess the feasibility, tolerability, and effectiveness of MB22001 microdosing in individuals with Major Depressive Disorder.
- A second Phase 2 trial is currently focusing on microdosing LSD in late-stage cancer patients facing existential distress.